**AEPC Webinars series**



**“Towards Precision Pediatrics: Advancements in Diagnosing and Monitoring Pediatric Pulmonary Hypertension"**

**20 March 2024 17:00-18:30 CET**

**In collaboration with ERN-Lung**

**Moderators:**

**Rolf M.F. Berger, Groningen, The Netherlands (r.m.f.berger@umcg.nl)**

**Damien Bonnet, Paris, France** (**damien.bonnet1@gmail.com)**

**Maurice Beghetti, Geneva, Switzerland (maurice.beghetti@hcuge.ch)**

**Presentation** (Julie Wacker; julie.wacker@hcuge.ch) (25 minutes)

“The importance of accurate diagnosing and phenotyping children with pulmonary hypertension”.

*Message:*

1. *the importance of adequate diagnostic work up in children with PH*

*(different PH-types: different pathophysiology, different natural course, different treatment; e.g. HPAH, PAH-CHD, portopulmonary hypertension, neonatal PH, developmental lung disease, pulm venous stenosis etc)*

1. *But also the importance of “deep phenotyping”: look for (and describe) associated co-morbidities, respiratory factors, genetic anomalies etc ; e.g TBX4 mutations.*

**Case presentation** (Julien Grynblat; julien.grynblat@inserm.fr) (15-20 minutes)

“Do we need invasive hemodynamics to not only diagnose but also monitor children with PAH during follow up?”

*Presentation of a case that illustrates the sense and nonsense of invasive hemodynamiscs in monitoring pediatric pulmonary arterial hypertension during follow up”*

**Presentation** (Menno Douwes; j.m.douwes@umcg.nl) (25 minutes)

“Individual tailoring of treatment strategies in children with PAH”

*Message:*

1. *the importance of risk-stratification and serial re-assessment,*
2. *how to do this in children?*

*current thoughts on risk factors, the use of risk scores and treatment algorithms in pediatric PAH; genetics in risk stratification? (may reflect on case presentation)*

**Discussion** ( +/- 20 minutes)